Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Primary concern | No. of reports | Secondary concern |
Lack of benefit | 74 | Battery depletion: n = 2 Generator displacement: n = 3 Electromagnetic interference: n = 7 Lead problem: n = 3 Pain: n = 43 Programming problems: n = 14 Other: n = 2 |
Pain or discomfort | 32 | Generator displacement: n = 1 Electromagnetic interference: n = 8 Lack of benefit: n = 11 Lead problem: n = 1 Pain (second type): n = 4 Programming problems: n = 5 Other: n = 2 |
Pocket site complications | 8 | Lack of benefit: n = 1 Lead problem: n = 2 Pain: n = 5 |
Lead problem | 5 | Generator displacement: n = 1 Lack of benefit: n = 3 Pain: n = 1 |
Programming problem | 4 | Electromagnetic interference: n = 2 Lack of benefit: n = 1 Pain: n = 1 |
- Citation: Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. World J Gastrointest Pharmacol Ther 2016; 7(2): 294-305
- URL: https://www.wjgnet.com/2150-5349/full/v7/i2/294.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i2.294